Water consumption impact on ALKS 5461 PK

Phase 1, randomised, open-label trial of buprenorphine + samidorphan in major depressive disorder (MDD), sponsored by Alkermes. Primary endpoints: Area under the plasma concentration-time curve from time zero to infinity at 72 hours, Area under the plasma concentration-time curve from time zero to the last measurable concentration at 72 hours and 1 more. Started Jul 2015; status: completed.